Healthcare / Health Information ServicesNasdaqCM
$0.19
-0.00 (-1.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-3.5M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$9M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-269.8%
↓Gross Margin
50.3%
↑Debt/Equity
0.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-23.8%
FCF / Net income
0.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.6M · net income $-14.7M · FCF $-3.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $14.6M | $14.6M | $10.4M | $5.8M | $6.4M | — |
| Net Income | $-14.7M | $-14.7M | $-57.7M | $-3.8M | $-836205.00 | — |
| EBITDA | $-9.2M | $-9.2M | $-57.8M | $-1.7M | $-1.6M | — |
| EPS | — | — | — | -0.26 | -0.06 | — |
| Gross Margin | 50.3% | 50.3% | 68.9% | 66.5% | 75.8% | — |
| Operating Margin | -65.6% | -65.6% | -44.9% | -31.0% | -23.0% | — |
| Net Margin | -100.6% | -100.6% | -553.7% | -65.3% | -13.1% | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.60 | 0.60 | -516.43 | -0.14 | 1.43 | — |
| Current Ratio | 0.41 | 0.41 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-3.5M | $-3.5M | $-5.8M | $-636930.00 | $-825776.00 | — |
| Returns | ||||||
| ROE | -269.8% | -269.8% | 312105.2% | 94.7% | -231.8% | — |
| Valuation | ||||||
| P/B | 1.14 | 1.14 | — | — | 433.79 | — |
| Growth & Yield | ||||||
| Revenue Growth | 40.3% | 40.3% | 80.7% | -9.6% | — | — |
| EPS Growth | — | — | — | -350.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-85.1%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-85.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.